Why Bristol-Myers Is Worth a Look

By Douglas Ehrman   Douglas is a member of The Motley Fool Blog Network — entries represent the personal opinions of our bloggers and are not formally edited. From time ...

Teva and Amarin Aren’t a Good Match

By Dan Carroll Small biotech Amarin (Nasdaq: AMRN  ) , the maker ofomega-3 drug Vascepa to treat cardiovascular disease, has been involved in a number of buyout-related discussions ...

Forest Labs submits cariprazine for FDA review

Forest Labs submits potential antipsychotic treatment cariprazine for FDA review By Associated Press NEW YORK (AP) — Forest Laboratories Inc. has submitted the potential oral ...

3 Attractive Stocks in BioPharma To Buy

By David Gould   David is a member of The Motley Fool Blog Network — entries represent the personal opinions of our bloggers and are not formally edited. BioPharma stocks ...

Smith & Nephew to Buy Healthpoint for $782 Million

By Andrea Gerlin (Bloomberg) -– Smith & Nephew Plc (SN/), Europe’s biggest maker of artificial hips and knees, agreed to buy closely held Healthpoint Biotherapeutics for ...

Nestle Forms Botanical-Medicine Venture With Li’s Chi-Med

By Makiko Kitamura & Dermot Doherty Nestle SA (NESN) and Hutchison China Meditech Ltd. (HCM), the drugmaker controlled by Hong Kong billionaire Li Ka-shing, agreed to form ...

Acadia Pharmaceuticals And Galena Biopharma: What A Difference A Trial Design Can Make

By Brian Nichols On Tuesday morning ACADIA Pharmaceuticals (ACAD) silenced its naysayers as it posted the largest one-day gain since Sarepta Pharmaceuticals (SRPT) rallied after announcing ...

Celsion’s Phase III Drug Trials For Thermodox

By Thomas Meyer Celsion (CLSN) closed at $7.58, down 2.8% with the 30 day Implied Volatility unchanged at 135. Celsion is an oncology drug development corporation focused on the development ...

Acadia Rockets Into The Stratosphere On Clinical Trial Data

By  Brian L. Wilson Yesterday morning we finally got to see the much anticipated data forAcadia Pharmaceuticals’ (ACAD) Phase III trial, which tested its flagship drug pimavanserin ...

10 top drug launch disasters

Payer risk looms large as biopharma marketing snafus highlight industry’s Achilles’ heel Just about everyone with even a slight amount of experience in the drug development ...

Edwards’ mitral heart valve wins Chinese SFDA nod

By Mark Hollmer Edwards Lifesciences ($EW) earned Chinese regulatory approval for its long-selling mitral heart valve, representing a major win for the device company during its push ...

St. Jude scores CE marks for implantable defibrillators

By Damian Garde   And, finally, some good news for St. Jude Medical’s ($STJ) cardiac business. The devicemaker won CE marks for three implantable defibrillators whose technology ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS